BTF's 2024 Updates on Hematology and Oncology, Fresno
This CME-accredited oncology conference, BTF's 2024 Updates on Hematology and Oncology, Fresno, is designed to improve the care of cancer patients by educating clinicians involved in cancer care.
The expert faculty will present a comprehensive overview of recent updates in hematology and oncology. The program will feature in-depth discussions and analyses of the latest scientific discoveries and advancements. Faculty will contextualize these findings within clinical practice and explore their potential to alter current standards of care. This conference is designed for physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals, providing them with the latest updates in the field. Emphasizing a multidisciplinary approach, it will showcase the integration of new advancements into patient-centered care.
Target Audience
- Medical oncologists
- Radiation oncologists
- Surgical oncologists
- Oncology residents/fellows
- Oncology NPs/PAs
- Oncology pharmacists
- Oncology nurses
Organizing Committee
Conference Director:
Binay Shah, MD, MHA - Binaytara Foundation
Conference Chair:
Sanjay Hinduja, MD - UCSF Fresno
Learning Objectives
At the conclusion of the activity, participants will be able to:
- Discuss new and updated treatment options for patients with hematologic malignancies and solid tumors
- Identify side effects, indications, and contra-indications of therapies used to diagnose and treat cancers
- Explain how to effectively manage side-effects associated with cancer treatment
GLOBAL ONCOLOGY PROJECT
Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/
August 3rd, 2024
All times are listed in Pacific Time (PT)
07:00 AM – 08:00 AM Registration, Breakfast, & Exhibits
08:00 AM – 08:05 AM Welcome
08:05 AM – 08:20 AM Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA
08:20 AM – 09:35 AM Session 1 - Hematologic Malignancies
Session Chair: Haifaa Abdulhaq, MD
08:20 AM – 08:45 AM MDS/Leukemias - Bart Scott, MD
08:45 AM – 09:10 AM Multiple Myeloma - Alfred Chung, MD
09:10 AM – 09:35 AM Lymphoma & CLL - Haifaa Abdulhaq, MD
09:35 AM – 10:05 AM Break & Exhibits
10:05 AM – 10:55 AM Session 2 - Thoracic Oncology
Session Chairs: Andy (Sew-Chung) Jang, MD & Ranjan Pathak, MD
10:05 AM – 10:30 AM Early-Stage Lung Cancer - Matthew Gubens, MD, MS, FASCO
10:30 AM – 10:55 AM Advanced Lung Cancer - Shiruyeh Schokrpur, MD, PhD
10:55 AM – 12:10 PM Session 3 - Case-Based Presentations
Session Chair: Sanjay Hinduja, MD
10:55 AM – 11:10 AM Case 1: Sarcoma - Varun Monga, MBBS
11:10 AM – 11:25 AM Case 2: Brain Tumor Updates - Jerome Graber, MD, MPH
11:25 AM – 11:40 AM Case 3: Head and Neck Cancer - Hyunseok Kang, MD, MPH, FACP
11:40 AM – 11:55 AM Case 4: Lung Cancer - Deepti Behl, MD
11:55 AM – 12:10 PM Q and A
12:10 PM – 01:10 PM Lunch & Exhibits
01:10 PM – 02:00 PM Session 4 - Genitourinary Cancer
Session Chair: Jude Khatib, MD
01:10 PM – 01:35 PM Kidney and Prostate Cancer - Jude Khatib, MD
01:35 PM – 02:00 PM Bladder Cancer - Mamta Parikh, MD, MS
02:00 PM – 02:50 PM Session 5 - GI Cancer
Session Chair: Jun Gong, MD
02:00 PM – 02:25 PM Upper GI Malignancies - Geoffrey Buckle, MD, MPH
02:25 PM – 02:50 PM Lower GI Malignancies - Jun Gong, MD
02:50 PM – 03:20 PM Break & Exhibits
03:20 PM – 04:10 PM Session 6 - Breast Cancer
Session Chair: Li Lisa Ge, MD
03:20 PM – 03:45 PM Non-Metastatic Breast Cancer - Shipra Gandhi, MD
03:45 PM – 04:10 PM Metastatic Breast Cancer - Mark Pegram, MD
04:10 PM Adjourn
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Binay Shah, MD, MHA
Sanjay Hinduja
Haifaa Abdulhaq, Clinical Professor, UCSF. Director of Hematology, UCSF Fresno. Director of Hematolog/Oncology Fellowship, UCSF Fresno
Alfred Chung, Assistant Professor
Li Ge, MD
Jun Gong, MD
Andy Jang, Assistant Professor of Medicine
Jude Khatib, MD
Ranjan Pathak, MBBS, MHS, FACP
Haifaa Abdulhaq, Clinical Professor, UCSF. Director of Hematology, UCSF Fresno. Director of Hematolog/Oncology Fellowship, UCSF Fresno
Geoffrey Buckle, MD, MPH
Shipra Gandhi, MD, MS
Jun Gong, MD
Matthew Gubens
Jude Khatib, MD
Mamta Parikh, MD,MS
Mark Pegram, MD
Shiruyeh Schokrpur, M.D., Ph.D.
Bart Scott, MD
DEEPTI BEHL, M.D.
Jerome Graber, MD, MPH, FAAN
Hyunseok Kang, MD, MPH
Varun Monga
Available Credit
- 5.75 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 5.75 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 5.75 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.75 Contact Hours.
Amgen Oncology | General Exhibit | Diane Leese |
Apellis | General Exhibit | Kathryn Larocca |
AstraZeneca | General Exhibit | Armando Pina |
Boehringer Ingelheim Pharmaceuticals, Inc. | General Exhibit | Todd Valdez |
Daiichi Sankyo | General Exhibit | Brandon Chors |
DSI 2nd Table | General Exhibit | Grant Garcia |
Eisai Oncology | General Exhibit | Brian Good |
Geron Corporation | General Exhibit | Brina Wright |
Gilead | General Exhibit | Olivia Lazaro-Delacerda |
Incyte | General Exhibit | Jason Roos |
Ipsen | General Exhibit | Lindsay Alistar |
Merck | General Exhibit | Wendy Leal |
Sanofi | General Exhibit | Collin Dumas |
Takeda | General Exhibit | Natalie Sweeney |
Price
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.